TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Jun 2, 2024--
United States United Kingdom Chelsea Tressler Daiichi Sankyo Brendan Mcevoy American Society Of Clinical Oncology
Source: joplinglobe.com